You Are Leaving Avistone's Website
You have selected a link that will take you to a site maintained by a third party. Avistone provides this link as a service to website visitors. Avistone is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click 'Cancel' to return to Avistone's site or 'Continue' to proceed.
2025 ASCO：Vebreltinib plus PLB1004 in EGFR-mutated NSCLC with Acquired MET Amplification or Overexpression after Failure on EGFR-TKI Treatment: A Phase Ib/II Study
Author：Caicu Zhou etc. Time：2025-05-31
Brief Information:
Vebreltinib and PLB1004 at RP2D demonstrates notable efficacy and manageable safety in EGFR-mutated NSCLC with METamp or METov after EGFR-TKIs failure. Findings from our phase Ib+II data suggest that NGS reported METamp+ could be utilized to identify target patients to receive combination of PLB1004 + Vebreltinib.
